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Purpose: Symptomatic vitreomacular adhesion (sVMA) comprises vitreomacular traction 
(VMT) and stage 1 and 2 full-thickness macular holes (MHs) associated with vitreomacular 
adhesion (VMA). We aimed to estimate the incidence and prevalence of sVMA in Germany.
Materials and methods: A systematic literature review was conducted to identify the 
incidence and prevalence of sVMA based on international epidemiologic studies, weighted 
for study size and then averaged across eligible studies. A second systematic review aimed to 
estimate the proportion of vitrectomy undertaken for sVMA in Germany. This was combined 
with the reported number of vitrectomies in Germany in 2016 to estimate the number of patients 
undergoing vitrectomy for sVMA.
Results: The prevalence of sVMA is 1,365 per 100,000 population, with an incidence of 6.96 
per 100,000 per year. For Germany, this translates to 1,119,300 cases, with 5,700 new cases 
reported annually. Analyzing the national hospital statistics, ~2,300 patients undergo vitrectomy 
due to sVMA in Germany each year, of which about 1,700 patients have VMT.
Conclusion: Incidence figures, driven by patients presenting to clinic, are much lower than 
expected based on population-based studies, suggesting that many patients with sVMA exist 
outside of the clinic system.
Keywords: epidemiology, vitreous body, vitreous pathology, vitreous adhesion, vitreous 
detachment, pars plana vitrectomy
Introduction
As part of normal aging, the vitreous body liquefies and usually starts to separate from 
the posterior retina, described as posterior vitreous detachment. Incomplete separation 
at the macula is described as vitreomacular adhesion (VMA), which is not, in itself, 
pathological and is, by definition, not associated with morphological alterations of 
the retina or functional loss. In contrast, if residual, focal, vitreomacular tractional 
(VMT) forces lead to a distortion of retinal tissue, visual symptoms may occur. This 
condition is described as VMT (syndrome). In the course of VMT, the development 
of a full-thickness macular hole (MH) may be observed. In the literature, VMT, with 
or without MH, is often referred to as symptomatic VMA (sVMA).
Structural changes are usually best seen using optical coherence tomography (OCT) 
and are characterized by retinal distortion, intraretinal cysts, and foveal elevation. 
Full-thickness MHs may retain vitreous traction, or this may subsequently pull free. 
Both VMT and MH may resolve spontaneously, although this becomes increasingly 
unlikely with increasing size or longer duration of an MH.1
Symptoms of sVMA typically include metamorphopsia and decreased distance and 
reading visual acuity,2 although some patients describe significant symptoms despite 
relatively well-preserved retinal structures. The indication of treatment of sVMA 
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is usually based on the patients’ complaints and function, 
and includes watchful waiting in less-pronounced cases, an 
intravitreal injection of a vitreolytic agent (ocriplasmin), or 
pars plana vitrectomy (PPV).1,3
While the epidemiology of MHs is relatively well 
documented, this is not always broken down by MH stage 
or the presence or absence of vitreous adhesion. Therefore, 
combined with incomplete epidemiological data on VMT, 
the overall epidemiological burden of sVMA is unclear. 
To address this uncertainty, Jackson et al completed a system-
atic review regarding the epidemiology of sVMA,4 which was 
published 5 years ago. One may hypothesize that since then, 
figures may have changed due to an aging population and, 
even more important, higher-resolution OCT imaging being 
available. Based on the developments of high-resolution 
imaging, the staging of these conditions was revisited and 
new classification systems for sVMA and MHs have been 
suggested.1,2,5 However, for the present investigation, we used 
the MH classification published by the American Academy of 
Ophthalmology (AAO).1 Given this background, we aimed 
to update Jackson’s analysis using international published 
data and then combine this with German vitrectomy data in 
order to estimate the burden of sVMA in Germany.
Materials and methods
Two systematic literature searches were conducted using the 
EMBASE and Medline databases and the Ovid interface. 
The first literature search targeted all eligible epidemiologic 
studies concerned with VMT and idiopathic MHs. The 
second collected all available data on MH staging and surgery 
in Germany. For the number of vitrectomies due to MH, we 
analyzed hospital data from the German national hospital 
reimbursement data.6
search for epidemiologic studies on VMT
In the first search, we used the following search terms in all 
search fields: vitreomacular traction, vitreoretinal traction, 
VMT, VMTS (vitreomacular traction syndrome), vitreomac-
ular adhesion, vitreoretinal adhesion, VMA, vitreous AND 
macula AND separation, vitreous detachment, retinal detach-
ment, macular detachment, macular hole, MH, retinal Hole, 
full-thickness macular hole, macular foramen and FTMH.
To filter for epidemiologic literature, we used the term 
“Epidemiology[MeSH:NoExp] OR Incidence[Title/abstract] 
OR Prevalence[Title/abstract] OR Epidemiology[Title/
abstract]” as proposed by Orphan.net.7 The details of the 
search strategies are shown in Table S1.
The search was conducted on February 19, 2018, by JM 
and AN, who independently sorted the articles and extracted 
the data. Differences were solved by discussion. To be 
included in the study, articles had to meet the inclusion and 
exclusion criteria listed in Table 1.
Mh stages in german vitrectomy patients
In the second search, we applied the following disease terms 
in all search fields: vitreomacular traction, vitreoretinal trac-
tion, VMT, VMTS, vitreomacular adhesion, vitreoretinal 
adhesion, macular hole, MH, Retinal Hole, full-thickness 
macular hole, macular foramen and FTMH. Defining the 
intervention, we used the terms “vitrectomy OR PPV OR pars 
plana OR surgery OR operation” in all fields and combined 
both searches using the AND operator.
The resulting set of articles was condensed by search-
ing for the term “German” in all search fields. The search 
was conducted on February 19, 2018, by JM and AN, who 
independently selected the articles and extracted the data. 
Differences were resolved by discussion. The articles were 
Table 1 exclusion and inclusion criteria for epidemiologic papers in VMT and Mh
Criterion Inclusion criteria Exclusion criteria
Population i1: adult patients with VMT e1: no adult patients with VMT
indication i2: Treatment of VMT in adults, also together with a 
macular hole equal to or smaller than 400 µm
e2: no treatment of VMT in adults, also together with a 
macular hole equal to or smaller than 400 µm
end points i3: epidemiologic measures
·	 incidence
·	 Prevalence
e3: no epidemiologic measure
Type of publication i4: Full-text publications e4: Publications, where no full text is available 
(eg, conference abstracts, letters)
Type of study i5: epidemiologic survey e5: Case studies, small case series, or studies not 
representative for the respective population
Date of publication i6: after 1996 e6: Before 1996
language i7: german or english e7: Other languages
Abbreviations: Mh, macular hole; VMT, vitreomacular traction.
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sorted based on the inclusion and exclusion criteria listed in 
Table 2. Search strategies are shown in detail in Table S2.
number of vitrectomies due to an Mh 
in germany
We determined the number of PPVs in Germany in 2016 for 
a VMT using data from the Institut für das Entgeltsystem im 
Krankenhaus (InEK), the institute that facilitates reimburse-
ment to hospitals. InEK collects all codes used by hospitals 
for billing of medical services.6 The codes used were ICD-10, 
Diagnosis Related Groups (DRG), and Operationen und 
Prozedurenschlüssel (OPS), all version 2016.
We filtered the data set for patients with the DRG 
codes C03A, C03B, or C03C indicating a retinal surgery. 
Two subsets were created using either the ICD-10 codes 
for macular pathology, H35.3 and H35.8, that include the 
diagnoses of VMT and MH, or the OPS codes for retinal 
surgery including macular manipulation 5-158.0, 5-158.1, 
5-158.2, 5-158.4, 5-158.x, 5-158.y. The OPS codes included 
all relevant PPVs.8 Finally, we searched for patient numbers 
emerging in both DRG code subsets, created using either the 
ICD-10 codes or the OPS codes. Those patients matching 
both criteria (diagnosis defined by ICD and procedure defined 
by OPS) were assumed to have undergone vitrectomy due to 
an MH, VMT, and/or epiretinal membrane as well as some 
less-frequent macular diseases. Distribution of MH stages 
from the systematic literature research was applied to derive 
numbers for stage 1 and 2 MH.
Results
VMT prevalence and incidence in 
population-based studies
The systematic literature search for international epide-
miologic studies resulted in 3,039 articles. This included 
1,409 duplicates that were identified by review of the title 
and abstract and then removed. The abstract and title search 
resulted in 43 articles for full-text screening, of which 12 met 
the eligibility and were included (Table 1). Figure 1 shows 
the flowchart of the systematic literature search.
Seven publications reported epidemiologic data on VMT 
and five on MH. Study details are shown in Table 3, listing 
design, population, sample size, diagnostic methods, and epi-
demiologic measures. With the exception of three studies,9–11 
all used OCT to diagnose VMT or MH. In most studies, the 
MH stage was not reported according to the current AAO 
classification.1
All studies included quite large population samples, with 
varying estimates of VMT prevalence that are summarized 
in Table 3. The incidence rate was estimated in only one 
study.4 For MH, both rates were estimated by at least three 
publications (Table 1). From the given rates, we calculated 
the arithmetic average (Table 3).
For VMT, we calculated from seven studies with a total 
of 18,859 participants (age range: 32–90 years) an average 
prevalence of 1.263 cases per 100,000. The incidence rate 
was reported by only one study with 0.56 cases per 100,000.4 
Averaging the data of five studies with a total of 123,621 par-
ticipants (age range: 26–90 years), we calculated an average 
prevalence for MH of 141 cases per 100,000 and an average 
annual incidence of 8.8 cases per 100,000.
We then aimed to refine these incidence and prevalence 
figures to consider just the subpopulation which had sVMA, 
namely, VMT with or without MH (Table 4). All patients 
with a diagnosis of VMT were included, while those patients 
diagnosed with an MH only (72.8%) had a concomitant VMT 
according to Jackson’s review of the literature.4 Therefore, 
the incidence and prevalence rates for MH were reduced to 
72.8% of their reported values in Table 4 to capture only 
Table 2 exclusion and inclusion criteria for german studies on Mh staging among the german patient population
Criterion Inclusion criterion Exclusion criterion
Population i1: adult patients for vitrectomy e1: no adult patients for vitrectomy
intervention i2: Vitrectomy e2: no vitrectomy
staging i3: Macular hole staging (after gass/aaO) e3: no macular hole staging (after gass/aaO)
Type of publication i4: Full-text publications e4: Publications, where no full-text is available 
(eg, conference abstracts, letters)
Type of study i5: epidemiologic survey e5: Case studies, small case series, or studies not 
representative for the respective population
language i7: german or english e7: Other languages
sample size i8: Patient number $5 e8: Patient number ,5
nationality i9: german patients e9: no german patients
Abbreviations: aaO, american academy of Ophthalmology; Mh, macular hole.
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those MHs with coexisting VMT. The resulting prevalence 
rate, including all cases of VMT plus all MH cases with 
coexisting VMT, was 1.365 cases per 100,000 inhabitants 
with an incidence rate of 6.96 new cases per 100,000 inhabit-
ants per year. Applied to the German population of roughly 
82 million, every year, about 5,700 new cases of sVMA 
would be observed. From the literature, a prevalent pool of 
1,119,300 patients is calculated.
Mh stages in german vitrectomy patients
The literature search about MH stage rates in Germany 
resulted in 719 hits containing 159 duplicates. From these, 31 
articles (Table 3) were included. Figure 2 shows the flowchart 
of the systematic literature search.
To estimate the surgical numbers for Germany based 
on real-world clinical data, we first made a literature search 
to determine the MH stage distribution of patients in 
Germany who underwent a PPV. Included studies are listed 
in Table 5, indicating sample size and staging distribution. 
For evaluation, we pooled the patients of stages 3 and 4 and 
calculated the weighted average.
About 77% of all patients receiving a PPV for MHs 
in Germany had a stage 3 or 4 MH. Therefore, 23% had a 
stage 1 or 2 MH, including VMT.
estimation of german VMT patients 
based on hospital surgery statistics
According to the INEK data, 52,223 patients underwent 
retinal surgery in Germany in 2016 and 34,314 of these 
underwent a PPV base on OPS codes. Of the 52,223 patients, 
about 15,878 had ICD-10 codes H35.3 or H35.8, indicating 
any macular changes, including VMT and MH, but also 
including patients with surgery for other macular changes 
such as epiretinal membrane. Selecting patients in the over-
lap of the ICD-10 and OPS subgroups resulted in a sample 
of 9,941 patients. This group most likely included patients 
who underwent a PPV for MH or VMT, but due to nonspe-
cific codes with the ICD-10 and OPS, it is likely that it also 
Figure 1 Flowchart of the systematic literature search on international epidemiology papers for VMT.
Abbreviation: VMT, vitreomacular traction.
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included patients with other macular diseases, in particular, 
epiretinal membrane.
Applying the stage distribution given in the literature 
(Table 5) to these 9,941 patients, 7,655 patients had a stage 3 
or 4 MH and 2,287 patients had an sVMA, that is, stage 1 
or 2 MH and/or a VMT. Considering that not all MHs show 
concomitant VMT, only 72.8% of patients with MH had 
concomitant VMT,4 the numbers for stage 1 or 2 MHs and a 
VMT reduced to 1,665 vitrectomies for patients with VMT 
or MH stages 1 or 2 with VMT in Germany.
Discussion
In the present work, we estimated the incidence and preva-
lence of VMT, with and without MH, based on 12 large 
international studies. We found a prevalence of 1,365 cases 
per 100,000 population and an incidence rate of 6.96 new 
cases per 100,000 population per year.
There is an apparent discrepancy between the incidence 
and prevalence rates, in that the prevalence is more than 
expected based on incident cases. There may be several 
reasons for this difference. First, the rate of spontaneous 
Table 4 summary of calculation of the prevalence and incidence of VMT from the literature estimates for VMT and Mh
Staging Population 
applicable (%)
VMT prevalence 
(per 100,000 inhabitants)a
VMT incidence 
(per 100,000 inhabitants)a
VMT: all stages 100 1,263 0.56
Mhs 72.8 102 6.4
sum 1,365 6.96
Note: aCalculated from weighted values found in the studies identified in the systematic literature search.
Abbreviations: Mh, macular hole; VMT, vitreomacular traction.
3XEOLFDWLRQVZHUHH[FOXGHGEDVHGRQWLWOHDQGDEVWUDFWLQIRUPDWLRQQ 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Q 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Figure 2 Flowchart of the systematic literature search on german papers staging Mh patients undergoing a vitrectomy.
Abbreviation: Mh, macular hole.
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Table 5 german studies on staging Mh patients undergoing PPV surgery
No Author, year Study design Patient 
number
Stage distribution in % Patients in % 
MH .400 µm
I II III IV Stages III and IV
1 Beutel et al, 200727 randomized clinical trial 40 0.0 5.0 77.5 17.5 95.0
2 Bopp et al, 199728 Prospective study 50 2.0 22.0 60.0 16.0 76.0
3 Brockmann et al, 201129 Prospective study 25 12.0 24.0 36.0 28.0 64.0
4 Brockmann et al, 201330 retrospective study 160 0.0 6.9 37.5 55.6 93.1
5 eckardt et al, 200831 Prospective study 33 0.0 45.5 27.3 27.3 54.6
6 eckardt and eckardt, 199532 Prospective study 37 5.4 48.6 35.1 10.8 45.9
7 engelmann et al, 201533 retrospective study 45 0.0 6.7 13.3 80.0 93.3
8 Faude et al, 199734 Prospective study 19 0.0 21.1 57.9 21.1 79.0
9 gass et al, 200335 retrospective cohort study 18 5.6 0.0 88.9 5.6 94.5
21 4.8 0.0 71.4 23.8 95.2
17 5.9 0.0 82.4 11.8 94.2
10 gehring et al, 199936 randomized clinical trial 19 0.0 21.1 47.4 31.6 79.0
11 göbel et al, 200037 retrospective cohort study 36 0.0 33.3 50.0 16.7 66.7
12 göbel and guthoff, 201038 retrospective cohort study 10 0.0 10 70.0 20.0 90.0
13 hager et al, 200539 retrospective cohort study 137 0.0 0.0 100.0 100.0
14 haritoglou et al, 200140 Prospective cohort study 105 0.0 7.6 78.1 14.3 92.4
15 haritoglou et al, 200641 Prospective study 14 0.0 0.0 100 100.0
16 hillenkamp et al, 200742 retrospective cohort study 28 0.0 28.6 71.4 71.4
17 hoerauf et al, 200143 Prospective study 44 0.0 27.3 47.7 25.0 72.7
18 Jenisch et al, 201744 retrospective study 225 0.0 52.0 32.0 16.0 48.0
19 Jordan et al, 201245 Prospective study 26 15.4 23.1 38.5 23.1 61.6
20 Krömer et al, 200446 Prospective study 20 0.0 0.0 100.0 0.0 100.0
21 Kristin et al, 200147 Prospective study 78 0.0 7.7 76.9 15.4 92.3
22 Kube et al, 200248 retrospective cohort study 107 0.0 63.6 33.6 2.8 36.4
23 Mayer et al, 201449 Prospective study 16 0.0 0.0 37.5 62.5 100.0
24 Meyer et al, 200850 Prospective study 91 0.0 12.1 56.1 31.8 87.9
25 rüfer et al, 200751 retrospective cohort study 61 0.0 11.5 77.0 11.5 88.5
26 remy et al, 200852 retrospective cohort study 14 0.0 28.6 35.7 35.7 71.4
27 schrader and schrenker, 199953 Prospective study 39 0.0 20.5 79.5 79.5
28 schumann et al, 200754 retrospective cohort study 96 0.0 0.0 80.2 19.8 100.0
29 Wirbelauer et al, 201155 Prospective study 21 0.0 25.0 75.0 0.0 75.0
30 Wirbelauer et al, 201656 Prospective study 47 0.0 36.2 63.8 0.0 63.8
31 Wolf et al, 200357 retrospective cohort study 37 0.0 35.1 56.8 8.1 64.9
Notes: Proportion of vitrectomized patients with an Mh at stages 3 and 4, arithmetic average=79.6%. Proportion of vitrectomized patients with an Mh at stages 3 and 4, 
weighted average=77.5%.
Abbreviations: Mh, macular hole; PPV, pars plana vitrectomy.
resolution of VMT (with or without MH) could be higher 
than previously assumed, and thus, only a small proportion 
of lesions that exist in the population-based studies (which 
drives our prevalence rates) progress to eye clinics/hospitals 
(which drives our incidence rates). This is possible as our 
understanding of the natural history of VMT and MH is 
largely based on clinical data, whereas the natural history 
of those outside of a clinic/hospital environment may differ. 
The use of OCT may also enable us to detect lesions much 
earlier than in previous studies, and earlier lesions might be 
more likely to resolve. Perhaps, the most likely explanation 
is that population-based studies may pick up asymptomatic 
cases that do not progress to intervention, unlike studies 
based on patients presenting to clinic or surgery.12–14 More 
epidemiologic studies are needed to determine the sVMA 
incidence rates.15
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Given the existing uncertainties of results from the 
systematic literature review, we aimed to further validate 
our results with other data sources: As one validation step, 
we considered the number of MH patients predicted by the 
literature with an incidence rate for MHs of 8.8 patients per 
100,000 adult inhabitants (Table 1), suggesting ~7,200 new 
MH patients for Germany per year. This is in good accor-
dance with 2016 German vitrectomy statistics, which suggest 
that 9,941 patients received surgery for MH or VMT – a fig-
ure that potentially also includes patients with other macular 
diseases, in particular, epiretinal membrane.
As another validation step, we considered a large vitreo-
retinal database study in the UK,4 which reported that 40.2% of 
PPVs with macular manipulation were for MH. For the 34,314 
German PPV patients with macular manipulation, the pool of 
MH patients would be 13,795, which is also in good accordance 
with the OPS/ICD filtered data figure of 15,878 patients. The 
same UK database study found that 14.2% of PPVs with macu-
lar manipulation were for VMT, suggesting that for Germany, 
2,255 of the 15,878 vitrectomy patients with macular manipula-
tion had VMT. These results are also concordant.
Weaknesses of this study include a reliance on certain 
assumptions. First, the AAO classification system describes 
stage 3 MHs (which we excluded) as those $400 µm in 
diameter with vitreomacular separation, but it is possible 
that some MHs .400 µm still had persisting VMA. Also, 
clinicians may have applied the classification systems vari-
ably, as more than one has evolved over time.1,3,16 Further, the 
measurement of MHs and their classification may be subject 
to significant interobserver variability. The clinical statistic 
reflects in-patient settings with vitrectomy only, while 
intravitreal gas or air injections are documented by several 
case series as the possible out-patient therapy for sVMA.17–20
Conclusion
While our estimated incidence of VMT (with and without 
MH) in Germany relies on a number of untested assumptions, 
it, nonetheless, shows that sVMA is an important disease 
affecting a large number of individuals, many of whom may 
be undiagnosed or exist outside of the clinic system.
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VMT epidemiology
Table S1 international epidemiology search
Databases: eMBase 1974–2018; Medline(r) 1946–2018
Search engine: Ovid
Date of search: February 19, 2018
Period searched: 1946–2018
Other filters: No filters
# syntax hits
#1 vitreomacular traction*.af 1,351
#2 Vitreo macular traction*.af 60
#3 VMT.af 945
#4 VMTs.af 43
#5 vitreomacular adhesion*.af 515
#6 vitreo macular adhesion*.af 8
#7 vitreous and macula* and separation.af 385
#8 VMa.af 2,970
#9 (vitreo-macular traction* or vitreoretinal traction* or vitreo-retinal traction*).af 623
#10 (vitreo-macular adhesion* or vitreoretinal adhesion* or vitreo-retinal adhesion).af 299
#11 macular hole*.af 8,139
#12 (retinal hole* or retinal break*).af 3,126
#13 Vitreous detachment*.af 3,080
#14 retinal detachment.af 44,383
#15 macular detachment*.af 1,317
#16 (Macula hole* or FTMh).af 4,774
#17 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 57,973
#18 (epidemiology or incidence or prevalence).af 5,210,928
#19 17 and 18 3,778
#20 limit 19 to yr=“1996–2018” 3,039
Supplementary materials
Table S2 german epidemiology search
Databases: eMBase 1974–2018 week 9, Medline 1947 to week 4, 2018, Medline epub ahead of print, in-process, and other non-indexed citation 
2014 to present
Search engine: Ovid
Date of search: February 19, 2018
Period searched: 1947–2018
Other filters: No filters
# syntax hits
#1 ((vitreomacula* or vitreoretinal or vitreo-macula* or vitreo macula* or vitreo retinal) and traction).af 2,553
#2 (VMT or VMTs).af 983
#3 (vitreomacula* adhesion* or vitreo macula* adhesion*).af 541
#4 (macula* hole* or macula* foramen or FTMh).af 9,071
#5 #1 Or #2 Or #3 Or # 11,446
#6 (vitrectomy or ppV or pars plana or surgery or operation).af 7,536,471
#7 #5 anD #6 7,882
#8 (((prospective or retrospective or cohort or observational or prognostic) and trial) or analysis or study or factor).af 28,747,371
#9 #14 anD #13 4,499
#10 german$.af 6,094,077
#11  10 anD 9 719
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